Aberdare Ventures

Gravie, Inc. is a health insurance platform based in Minneapolis, Minnesota, that provides health insurance plans for individuals, families, and employers. Established in 2013, Gravie enables users to compare insurance options available through government-run marketplaces as well as directly from insurance companies. The company specializes in designing tailored benefits plans for employees, managing payments, and offering year-round support. Its services include Gravie Care, which allows individuals to shop for their benefits, and it utilizes a mobile application and website for ease of access. Gravie's innovative approach includes a defined contribution model, allowing employers to set fixed annual budgets for health benefits while providing tools for effective cost management. The platform also facilitates a better understanding of healthcare expenses through detailed price comparisons and information on co-pays, co-insurance, and applicable tax credits.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

Jiff, Inc. is a technology company that specializes in providing a HIPAA-compliant platform for the healthcare industry, enabling the creation of personalized and private communities of care. Founded in 2010 and headquartered in Mountain View, California, Jiff focuses on enhancing communication between healthcare professionals and patients through innovative tools. One of its notable products is JiffPad, an educational platform for iPads that transforms doctor-patient conversations and images into videos, facilitating easier sharing and understanding within the privacy of patients' homes. The company also offers solutions that engage employees by linking company benefits and incentives to healthy behaviors, leveraging familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, furthering its mission to improve healthcare delivery and employee engagement. As of April 2017, Jiff operates as a subsidiary of Castlight Health, Inc.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

Gravie, Inc. is a health insurance platform based in Minneapolis, Minnesota, that provides health insurance plans for individuals, families, and employers. Established in 2013, Gravie enables users to compare insurance options available through government-run marketplaces as well as directly from insurance companies. The company specializes in designing tailored benefits plans for employees, managing payments, and offering year-round support. Its services include Gravie Care, which allows individuals to shop for their benefits, and it utilizes a mobile application and website for ease of access. Gravie's innovative approach includes a defined contribution model, allowing employers to set fixed annual budgets for health benefits while providing tools for effective cost management. The platform also facilitates a better understanding of healthcare expenses through detailed price comparisons and information on co-pays, co-insurance, and applicable tax credits.

goBalto, Inc. is a cloud-based software company that specializes in streamlining clinical trials for the pharmaceutical, biotechnology, and medical device industries. Founded in 2008 and headquartered in San Francisco, California, the company offers a suite of solutions designed to enhance the efficiency of clinical research. Its key products include Select, which assists in identifying ideal study sites and target populations through data analysis; Activate, which facilitates rapid initiation of studies for sponsors, contract research organizations, and investigative sites; and Analyze, which provides real-time insights and status updates to improve operational processes. Additionally, goBalto's offerings encompass operational performance, oversight, risk management, business intelligence, and compliance solutions. The company also has offices in Singapore and King of Prussia, Pennsylvania, and operates as a subsidiary of Oracle Corporation.

Jiff, Inc. is a technology company that specializes in providing a HIPAA-compliant platform for the healthcare industry, enabling the creation of personalized and private communities of care. Founded in 2010 and headquartered in Mountain View, California, Jiff focuses on enhancing communication between healthcare professionals and patients through innovative tools. One of its notable products is JiffPad, an educational platform for iPads that transforms doctor-patient conversations and images into videos, facilitating easier sharing and understanding within the privacy of patients' homes. The company also offers solutions that engage employees by linking company benefits and incentives to healthy behaviors, leveraging familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, furthering its mission to improve healthcare delivery and employee engagement. As of April 2017, Jiff operates as a subsidiary of Castlight Health, Inc.

Gravie, Inc. is a health insurance platform based in Minneapolis, Minnesota, that provides health insurance plans for individuals, families, and employers. Established in 2013, Gravie enables users to compare insurance options available through government-run marketplaces as well as directly from insurance companies. The company specializes in designing tailored benefits plans for employees, managing payments, and offering year-round support. Its services include Gravie Care, which allows individuals to shop for their benefits, and it utilizes a mobile application and website for ease of access. Gravie's innovative approach includes a defined contribution model, allowing employers to set fixed annual budgets for health benefits while providing tools for effective cost management. The platform also facilitates a better understanding of healthcare expenses through detailed price comparisons and information on co-pays, co-insurance, and applicable tax credits.

goBalto, Inc. is a cloud-based software company that specializes in streamlining clinical trials for the pharmaceutical, biotechnology, and medical device industries. Founded in 2008 and headquartered in San Francisco, California, the company offers a suite of solutions designed to enhance the efficiency of clinical research. Its key products include Select, which assists in identifying ideal study sites and target populations through data analysis; Activate, which facilitates rapid initiation of studies for sponsors, contract research organizations, and investigative sites; and Analyze, which provides real-time insights and status updates to improve operational processes. Additionally, goBalto's offerings encompass operational performance, oversight, risk management, business intelligence, and compliance solutions. The company also has offices in Singapore and King of Prussia, Pennsylvania, and operates as a subsidiary of Oracle Corporation.

Advance Medical, established in 1999, is a prominent global provider of telemedicine services, specializing in expert medical opinions delivered by board-certified physicians. The company offers employers and insurers worldwide access to top-quality medical advice via offices across the U.S., Europe, Asia, and South America. Its unique model ensures that every patient receives personalized attention through phone or video consultations, enabling accurate diagnoses, tailored treatment plans, and guidance on suitable healthcare facilities.

Adavium Medical is a medical equipment and diagnostics company based in São Paulo, Brazil, established in 2011. The company focuses on commercializing an innovative portfolio of medical devices and diagnostic products, representing leading international manufacturers. With a workforce of over 300 employees, Adavium Medical operates a fully-integrated commercial platform that adheres to high standards. It boasts the largest customer base in Brazil, serving more than 2,500 clients in both premium and long-tail segments of the medical equipment and diagnostics market. This extensive reach significantly surpasses that of typical distributors and multinational companies in the region, positioning Adavium Medical as a key player in a fragmented industry.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Cervel Neurotech, based in San Mateo, California, is a privately-held medical device company founded in 2008 by Drs. M. Bret Schneider and David J. Mishelevich, along with entrepreneur Michael J. Partsch. The company specializes in pioneering non-invasive deep brain neuro-modulation technologies, primarily focusing on repetitive transcranial magnetic stimulation (rTMS). Cervel's proprietary Steerable TMS device aims to treat psychiatric and neurological illnesses more effectively by precisely targeting specific brain areas while minimizing unintended stimulation. This targeted approach enables quicker treatment initiation and enhances the likelihood of successful outcomes. The company was acquired by Rio Grande Neurosciences in 2015.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

goBalto, Inc. is a cloud-based software company that specializes in streamlining clinical trials for the pharmaceutical, biotechnology, and medical device industries. Founded in 2008 and headquartered in San Francisco, California, the company offers a suite of solutions designed to enhance the efficiency of clinical research. Its key products include Select, which assists in identifying ideal study sites and target populations through data analysis; Activate, which facilitates rapid initiation of studies for sponsors, contract research organizations, and investigative sites; and Analyze, which provides real-time insights and status updates to improve operational processes. Additionally, goBalto's offerings encompass operational performance, oversight, risk management, business intelligence, and compliance solutions. The company also has offices in Singapore and King of Prussia, Pennsylvania, and operates as a subsidiary of Oracle Corporation.

MC10, Inc. is a company that specializes in developing wearable medical sensors designed to collect clinical-grade biometric and physiological data. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of innovative products, including BioStamp nPoint for vital signs and activity monitoring, Kintinuum for orthopedic rehabilitation, WiSP for cardiac monitoring, and BioStampMD, a conformal sensor that gathers both objective and subjective health data. MC10 employs advanced flexible electronics technology, allowing its devices to bend and stretch with the body, ensuring comfort and ease of use. The company focuses on enhancing human capabilities and improving health insights through discreet, location-specific sensing that captures real-world data on muscle activation and movement, with applications extending across various sectors including sports, military, and energy.

Wello is an online platform offering live fitness training over two-way video. It provides an affordable and easy way for its users to workout with a live fitness professional of their choice. Its first product called 1-on-1 personal training was launched in 2012. In 2013, Wello completed the program at Rock Health and became part of a prolific network of the best digital health companies in the country. It matches clients with the right Wello-vetted trainer and workout program for them, provides seamless scheduling and payment, and establishes the live video connection for the workout to take place. Wello was launched in 2011 by Stanford MBA students Ann Scott Plante and Leslie Silverglide. It is based in San Francisco, C.A.

Bluesight operates as a healthcare technology company specializing in supply chain optimization for pharmaceuticals. It offers Medication Intelligence solutions that provide real-time analytics across the entire medication lifecycle, enhancing efficiency, reducing risks, and improving patient safety within hospitals. The core product is an inventory management platform that automates pharmacy kit processing and medication tracking, replacing manual processes to increase operational efficiency and medication visibility.

RxAnte Inc. is a healthcare analytics company based in Portland, Maine, founded in 2008. It specializes in predictive analytics and targeted clinical programs designed to enhance medication prescribing and adherence for health plans and their members. The company's platform effectively identifies patients who may benefit from interventions, enabling healthcare providers to monitor and manage medication programs over time. A key feature of RxAnte's offerings is the Mosaic Pharmacy Service, which focuses on delivering a superior pharmacy experience to complex and vulnerable patients. This service collaborates with prescribers and caregivers to ensure that medication regimens are safer, simpler, and more affordable, ultimately improving clinical quality and reducing overall healthcare costs. RxAnte operates as a subsidiary of Millennium Laboratories, Inc.

Jiff, Inc. is a technology company that specializes in providing a HIPAA-compliant platform for the healthcare industry, enabling the creation of personalized and private communities of care. Founded in 2010 and headquartered in Mountain View, California, Jiff focuses on enhancing communication between healthcare professionals and patients through innovative tools. One of its notable products is JiffPad, an educational platform for iPads that transforms doctor-patient conversations and images into videos, facilitating easier sharing and understanding within the privacy of patients' homes. The company also offers solutions that engage employees by linking company benefits and incentives to healthy behaviors, leveraging familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, furthering its mission to improve healthcare delivery and employee engagement. As of April 2017, Jiff operates as a subsidiary of Castlight Health, Inc.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

MC10, Inc. is a company that specializes in developing wearable medical sensors designed to collect clinical-grade biometric and physiological data. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of innovative products, including BioStamp nPoint for vital signs and activity monitoring, Kintinuum for orthopedic rehabilitation, WiSP for cardiac monitoring, and BioStampMD, a conformal sensor that gathers both objective and subjective health data. MC10 employs advanced flexible electronics technology, allowing its devices to bend and stretch with the body, ensuring comfort and ease of use. The company focuses on enhancing human capabilities and improving health insights through discreet, location-specific sensing that captures real-world data on muscle activation and movement, with applications extending across various sectors including sports, military, and energy.

Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

NxThera, founded in 2008 and headquartered in Maple Grove, Minnesota, specializes in the development of medical technologies for treating endourological conditions. The company's core technology involves convective water vapor energy, designed to deliver minimally invasive, thermal therapy for conditions such as benign prostatic hyperplasia (BPH), which affects over 32 million men in the U.S. As of April 30, 2018, NxThera operates as a subsidiary of Boston Scientific Corporation.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Posit Science Corporation, founded in 2002 and headquartered in San Francisco, California, specializes in brain training software designed to enhance cognitive performance. The company offers clinically proven programs that leverage advancements in brain plasticity—the brain's capacity to adapt and change—to improve cognitive functions such as speed, attention, and memory. By providing exercises through its website, Posit Science aims to help individuals maintain and enhance their cognitive abilities throughout their lives, facilitating better real-world performance. Originally known as Neuroscience Solutions Corporation, the company adopted its current name in January 2005.

Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in the development of innovative therapeutics for the treatment of liver diseases. Founded in 2005 and headquartered in San Diego, California, the company is primarily focused on advancing treatments for conditions such as hepatitis C virus infection, portal hypertension, and liver fibrosis associated with nonalcoholic steatohepatitis. Its lead product candidate, Emricasan, is an orally active caspase protease inhibitor currently undergoing Phase IIb clinical trials. Additionally, Conatus is developing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage aimed at addressing chronic diseases linked to inflammasome pathways. The company also has a collaboration agreement with Novartis to conduct multiple Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.

Vertiflex Inc., established in 2005 and headquartered in Carlsbad, California, is a medical device company specializing in minimally invasive spinal surgery technologies. The company's primary product is the Superion Interspinous Spacer, a titanium implant designed to treat moderate lumbar spinal stenosis by fitting between the spinous processes in the lumbar spine. This motion-preserving solution offers an indirect decompression system, providing an alternative treatment option for patients with lumbar stenosis who may not require traditional spine surgery. As of June 11, 2019, Vertiflex Inc. operates as a subsidiary of Boston Scientific Corporation.

Jiff, Inc. is a technology company that specializes in providing a HIPAA-compliant platform for the healthcare industry, enabling the creation of personalized and private communities of care. Founded in 2010 and headquartered in Mountain View, California, Jiff focuses on enhancing communication between healthcare professionals and patients through innovative tools. One of its notable products is JiffPad, an educational platform for iPads that transforms doctor-patient conversations and images into videos, facilitating easier sharing and understanding within the privacy of patients' homes. The company also offers solutions that engage employees by linking company benefits and incentives to healthy behaviors, leveraging familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, furthering its mission to improve healthcare delivery and employee engagement. As of April 2017, Jiff operates as a subsidiary of Castlight Health, Inc.

EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Clovis Oncology, Inc. is a biopharmaceutical company dedicated to acquiring, developing, and commercializing innovative cancer treatments in the United States, Europe, and other international markets. The company focuses on precision medicine, targeting specific cancer subsets to ensure that therapeutics are directed to patients who are most likely to benefit. Clovis Oncology's primary product is Rubraca, an oral small molecule inhibitor of poly ADP-ribose polymerase, approved for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Additionally, the company is developing lucitanib, an oral inhibitor targeting multiple tyrosine kinase receptors involved in cancer progression. Clovis distributes its products through specialty distributors and pharmacy providers, and it engages in various collaborations and licensing agreements with prominent pharmaceutical companies such as Pfizer, AstraZeneca, and Bristol-Myers Squibb. Founded in 2009 and headquartered in Boulder, Colorado, Clovis Oncology is committed to advancing cancer care through targeted therapeutic approaches.

Posit Science Corporation, founded in 2002 and headquartered in San Francisco, California, specializes in brain training software designed to enhance cognitive performance. The company offers clinically proven programs that leverage advancements in brain plasticity—the brain's capacity to adapt and change—to improve cognitive functions such as speed, attention, and memory. By providing exercises through its website, Posit Science aims to help individuals maintain and enhance their cognitive abilities throughout their lives, facilitating better real-world performance. Originally known as Neuroscience Solutions Corporation, the company adopted its current name in January 2005.

Mpex Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies to address the increasing challenge of antibiotic resistance, particularly in gram-negative bacteria. The company focuses on enhancing existing antibiotics by utilizing proprietary formulations, pharmacokinetic and pharmacodynamic strategies, and novel potentiating agents to effectively inhibit the molecular mechanisms that contribute to resistance. One of its key products is MP-376, a proprietary formulation of levofloxacin designed as a maintenance therapy to prevent bacterial exacerbations in patients suffering from cystic fibrosis and chronic obstructive pulmonary disease.

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule therapeutics based on its unique boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis, a fungal infection of the toenails. Anacor's lead product candidate, crisaborole topical ointment, is an anti-inflammatory therapy currently undergoing Phase III clinical trials for mild-to-moderate atopic dermatitis and psoriasis. Additionally, the company is developing AN3365, an antibiotic aimed at treating infections caused by Gram-negative bacteria. Anacor has established collaboration agreements with various organizations to advance drug candidates targeting diseases such as African trypanosomiasis, tuberculosis, and other neglected tropical diseases. Founded in 2000 and headquartered in Palo Alto, California, Anacor Pharmaceuticals was previously known as AnaMax, Inc. and became a subsidiary of Pfizer Inc. in 2016.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

Cervel Neurotech, based in San Mateo, California, is a privately-held medical device company founded in 2008 by Drs. M. Bret Schneider and David J. Mishelevich, along with entrepreneur Michael J. Partsch. The company specializes in pioneering non-invasive deep brain neuro-modulation technologies, primarily focusing on repetitive transcranial magnetic stimulation (rTMS). Cervel's proprietary Steerable TMS device aims to treat psychiatric and neurological illnesses more effectively by precisely targeting specific brain areas while minimizing unintended stimulation. This targeted approach enables quicker treatment initiation and enhances the likelihood of successful outcomes. The company was acquired by Rio Grande Neurosciences in 2015.

Vertiflex Inc., established in 2005 and headquartered in Carlsbad, California, is a medical device company specializing in minimally invasive spinal surgery technologies. The company's primary product is the Superion Interspinous Spacer, a titanium implant designed to treat moderate lumbar spinal stenosis by fitting between the spinous processes in the lumbar spine. This motion-preserving solution offers an indirect decompression system, providing an alternative treatment option for patients with lumbar stenosis who may not require traditional spine surgery. As of June 11, 2019, Vertiflex Inc. operates as a subsidiary of Boston Scientific Corporation.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Ablation Frontiers, Inc. is a medical device company located in Carlsbad, California, focused on developing innovative solutions for individuals suffering from atrial fibrillation (AF) and other cardiac arrhythmias. The company specializes in manufacturing mapping and ablation catheters, radiofrequency generators, and related accessories designed to assist healthcare professionals in effectively treating these conditions. In 2006, Ablation Frontiers received CE Mark approval to market its catheter system and the GENius Radiofrequency Generator in the European Union for the treatment of supraventricular arrhythmias and atrioventricular node ablation. Currently, the company is conducting a clinical trial under a United States Food and Drug Administration investigational device exemption to secure approval for its catheter system for use in chronic AF in the U.S. However, its products are not yet approved for marketing or sales in the United States.

Paracor Medical is a medical device company established in 1999 that specializes in developing innovative, technology-driven solutions for the treatment of heart failure. The company focuses on creating alternatives to traditional open chest surgery, aiming to alleviate the burden on patients with failing heart muscles. By employing a mechanical approach, Paracor Medical seeks to enhance the effectiveness of heart failure treatment while minimizing the invasiveness of procedures.

Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in the development of innovative therapeutics for the treatment of liver diseases. Founded in 2005 and headquartered in San Diego, California, the company is primarily focused on advancing treatments for conditions such as hepatitis C virus infection, portal hypertension, and liver fibrosis associated with nonalcoholic steatohepatitis. Its lead product candidate, Emricasan, is an orally active caspase protease inhibitor currently undergoing Phase IIb clinical trials. Additionally, Conatus is developing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage aimed at addressing chronic diseases linked to inflammasome pathways. The company also has a collaboration agreement with Novartis to conduct multiple Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.

Vertiflex Inc., established in 2005 and headquartered in Carlsbad, California, is a medical device company specializing in minimally invasive spinal surgery technologies. The company's primary product is the Superion Interspinous Spacer, a titanium implant designed to treat moderate lumbar spinal stenosis by fitting between the spinous processes in the lumbar spine. This motion-preserving solution offers an indirect decompression system, providing an alternative treatment option for patients with lumbar stenosis who may not require traditional spine surgery. As of June 11, 2019, Vertiflex Inc. operates as a subsidiary of Boston Scientific Corporation.

Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.

NBI Development is an implantable medical device company focused on the development of novel neuromodulation therapies. The company develops neuromodulation, the use of electrical impulses to manage activity in the nervous system.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

Posit Science Corporation, founded in 2002 and headquartered in San Francisco, California, specializes in brain training software designed to enhance cognitive performance. The company offers clinically proven programs that leverage advancements in brain plasticity—the brain's capacity to adapt and change—to improve cognitive functions such as speed, attention, and memory. By providing exercises through its website, Posit Science aims to help individuals maintain and enhance their cognitive abilities throughout their lives, facilitating better real-world performance. Originally known as Neuroscience Solutions Corporation, the company adopted its current name in January 2005.

Kémia operates as a pharmaceutical company. The company discovers and develops small molecule therapeutics. It offers allosteric kinase inhibitors for the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as for cardiovascular and metabolic conditions; and modulators of G protein-coupled receptors. The company specializes in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.

KAI Pharmaceuticals is a drug discovery and development company focused on creating innovative therapeutics for cardiovascular disease, kidney disease, and pain management. The company's lead product candidate, KAI-9803, is undergoing a Phase 2b clinical trial aimed at evaluating its ability to reduce myocardial injury in patients experiencing heart attacks. Additionally, KAI is advancing its second core program, KAI-4169, which targets secondary hyperparathyroidism in kidney disease patients and is anticipated to enter human clinical trials. The company is also exploring pain management through its ongoing program, KAI-1678, currently in Phase 2a testing.

Mpex Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies to address the increasing challenge of antibiotic resistance, particularly in gram-negative bacteria. The company focuses on enhancing existing antibiotics by utilizing proprietary formulations, pharmacokinetic and pharmacodynamic strategies, and novel potentiating agents to effectively inhibit the molecular mechanisms that contribute to resistance. One of its key products is MP-376, a proprietary formulation of levofloxacin designed as a maintenance therapy to prevent bacterial exacerbations in patients suffering from cystic fibrosis and chronic obstructive pulmonary disease.

Vertiflex Inc., established in 2005 and headquartered in Carlsbad, California, is a medical device company specializing in minimally invasive spinal surgery technologies. The company's primary product is the Superion Interspinous Spacer, a titanium implant designed to treat moderate lumbar spinal stenosis by fitting between the spinous processes in the lumbar spine. This motion-preserving solution offers an indirect decompression system, providing an alternative treatment option for patients with lumbar stenosis who may not require traditional spine surgery. As of June 11, 2019, Vertiflex Inc. operates as a subsidiary of Boston Scientific Corporation.

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule therapeutics based on its unique boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis, a fungal infection of the toenails. Anacor's lead product candidate, crisaborole topical ointment, is an anti-inflammatory therapy currently undergoing Phase III clinical trials for mild-to-moderate atopic dermatitis and psoriasis. Additionally, the company is developing AN3365, an antibiotic aimed at treating infections caused by Gram-negative bacteria. Anacor has established collaboration agreements with various organizations to advance drug candidates targeting diseases such as African trypanosomiasis, tuberculosis, and other neglected tropical diseases. Founded in 2000 and headquartered in Palo Alto, California, Anacor Pharmaceuticals was previously known as AnaMax, Inc. and became a subsidiary of Pfizer Inc. in 2016.

Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.

IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule therapeutics based on its unique boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis, a fungal infection of the toenails. Anacor's lead product candidate, crisaborole topical ointment, is an anti-inflammatory therapy currently undergoing Phase III clinical trials for mild-to-moderate atopic dermatitis and psoriasis. Additionally, the company is developing AN3365, an antibiotic aimed at treating infections caused by Gram-negative bacteria. Anacor has established collaboration agreements with various organizations to advance drug candidates targeting diseases such as African trypanosomiasis, tuberculosis, and other neglected tropical diseases. Founded in 2000 and headquartered in Palo Alto, California, Anacor Pharmaceuticals was previously known as AnaMax, Inc. and became a subsidiary of Pfizer Inc. in 2016.

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule therapeutics based on its unique boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis, a fungal infection of the toenails. Anacor's lead product candidate, crisaborole topical ointment, is an anti-inflammatory therapy currently undergoing Phase III clinical trials for mild-to-moderate atopic dermatitis and psoriasis. Additionally, the company is developing AN3365, an antibiotic aimed at treating infections caused by Gram-negative bacteria. Anacor has established collaboration agreements with various organizations to advance drug candidates targeting diseases such as African trypanosomiasis, tuberculosis, and other neglected tropical diseases. Founded in 2000 and headquartered in Palo Alto, California, Anacor Pharmaceuticals was previously known as AnaMax, Inc. and became a subsidiary of Pfizer Inc. in 2016.

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

Pharmion is a global biotech company that is dedicated to the hematology and oncology communities. We work in partnership with a network of scientific and clinical advisors to identify and develop products for global hematology and oncology markets. To expand each product's potential, we have established our own regulatory, development and sales and marketing organizations in the United States, Europe, and Australia, and we have developed a third-party distributor network to serve the hematology and oncology markets in 20 additional countries throughout the Middle East, Asia, and Latin America. The global capabilities within our sales, marketing and distribution organization distinguishes us from other companies of a similar size. With our international network we can reach physicians and their patients in more than 30 countries. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on licensing, developing, and commercializing therapeutic products for the treatment of hematology and oncology patients. Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients’ quality of life.

Microbia an industrial biotechnology company, engages in the development, production, and commercialization of specialty ingredients and biomaterials utilizing fermentation technology. Its products include carotenoids, specialty ingredients, biopolymers, and other biomaterials. The company has a strategic alliance with Tate & Lyle Investments, Ltd. to develop and commercialize fermentation-derived renewable ingredients.

Alibris is an online marketplace that specializes in connecting independent sellers of new and used books, music, and movies with buyers around the world. Established in November 1998, the company has grown to become the largest independently owned and operated marketplace of its kind on the Internet, offering over 100 million items from thousands of sellers. Alibris focuses on providing access to a wide range of titles, including rare and collectible works, making it a valuable resource for enthusiasts and collectors. By facilitating direct transactions between sellers and buyers, Alibris fosters a community of individuals who share a passion for literature, music, and film.

CapitalThinking is a New York-based mortgage financial services company founded in 1999. It specializes in providing fixed and flexible payment solutions to its clients through an online platform that facilitates applications and quotations. In addition to its mortgage services, CapitalThinking develops application software tailored for the financial services industry, focusing on compliance and risk management. This software offers comprehensive features for enterprise-wide, customer-centric, process-integrated credit and operational risk management. The company was acquired by CapitalStream in January 2004, further enhancing its capabilities in the financial sector.